Jing Li

US Patent:

20220373539, Nov 24, 2022

Filed:

May 24, 2021

Appl. No.:

17/328816

Inventors:

- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Wilmington DE, US
Jing Li - Wilmington DE, US
Inna Vainshtein - Wilmington DE, US
Jingjing Chen - Gaithersburg MD, US

International Classification:

G01N 33/53
C07K 16/24
A61P 1/04

Abstract:

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

US Patent:

20230129381, Apr 27, 2023

Filed:

Sep 14, 2022

Appl. No.:

17/944506

Inventors:

- Washington DC, US
JING LI - Arlington VA, US
YILIANG LI - Tianjin, CN

International Classification:

C07F 5/02
A61K 31/69
C07D 311/02
A61P 35/00

Abstract:

Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to one or more anticancer drugs, such as platinum-based chemotherapeutics.

US Patent:

20230012172, Jan 12, 2023

Filed:

Aug 22, 2022

Appl. No.:

17/892948

Inventors:

- Washington DC, US
Jing LI - Arlington VA, US
Ruiqin WU - Sichuan, CN
Yiliang LI - Hebei, CN

International Classification:

C07C 233/58
C07C 235/74
C07C 235/88
C07C 235/26
A61K 31/16
A61K 31/22
A61K 31/27

Abstract:

Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to platinum-based chemotherapy. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative in combination with at least one platinum-based chemotherapeutic separately or in a combination therapy. In some embodiments, methods of treating tumors disclosed herein can include screening and/or selecting a subject suitable for treatment on the basis of SENP1 tumor expression. In other embodiments, methods of treating tumors can include administering a composition disclosed herein to a subject, the composition having a combination of at least one ursolic acid derivative and at least one platinum-based chemotherapeutic.

US Patent:

20210340200, Nov 4, 2021

Filed:

Sep 25, 2019

Appl. No.:

17/279772

Inventors:

- Gaithersburg MD, US
Marius ALBULESCU - Gaithersburg MD, US
Jing LI - Gaithersburg MD, US
Ethan GRANT - Gaithersburg MD, US
Katie STREICHER - Gaithersburg MD, US
Gabor ILLEI - Gaithersburg MD, US
Liangwei WANG - Gaithersburg MD, US
William REES - Gaithersburg MD, US

International Classification:

C07K 14/47
A61P 37/06
C12N 9/26
C12N 9/16
C12N 15/86

Abstract:

A human CD40L-specific Tn3 molecule and therapeutic uses thereof.

US Patent:

20200262907, Aug 20, 2020

Filed:

Dec 16, 2016

Appl. No.:

16/063803

Inventors:

- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Gaithersburg MD, US
Jing Li - Gaithersburg MD, US
Inna Vainshtein - Gaithersburg MD, US
Jinging Chen - Gaithersburg MD, US

International Classification:

C07K 16/24
G01N 33/68

Abstract:

The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

US Patent:

20200071351, Mar 5, 2020

Filed:

Dec 15, 2017

Appl. No.:

16/469064

Inventors:

Antonius Ola - Naikoten I Kupang, ID
Samantha S.M. Yee - San Antonio TX, US
- Austin TX, US
- Norman OK, US
Jing Li - Columbia MD, US
Jiangnan Peng - Columbia MD, US

International Classification:

C07J 71/00
C07J 17/00
A61P 35/00

Abstract:

This present disclosure relates to the fields of medicine and pharmaceuticals. In particular, the invention relates to the identification of epoxytaccalonolide microtubule stabilizers for use in inhibiting cell proliferation and disrupting normal cellular microtubule processes leading to cell death. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20180252728, Sep 6, 2018

Filed:

Sep 16, 2016

Appl. No.:

15/759330

Inventors:

- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Gaithersburg MD, US
Jing Li - Gaithersburg MD, US
Inna Vainshtein - Gaithersburg MD, US
Jingjing Chen - Gaithersburg MD, US

International Classification:

G01N 33/68
C07K 16/24

Abstract:

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.